Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene (This gene does not contain this module)
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target

Gene: RPS5

Summary for RPS5

Gene information	Gene symbol	RPS5
	Ensembl ID	ENSG00000083845
	Entrez ID	6193
	Gene name	ribosomal protein S5
	Synonyms	S5
	Gene type	protein_coding
	UniProtAcc	P46782

Top

Dataset with differentially expressed gene: RPS5

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE186960	Panc1 cell line	Cell line	Pancreatic cancer	Pancreatic ductal adenocarcinoma (PDAC)	Chemotherapy	gemcitabine	NA	Malignant cells	-0.6165	0.00e+00
GSE163836	FCIBC02 cell line	Cell line	Breast cancer	Inflammatory breast cancer	Chemotherapy	paclitaxel	NA	Malignant cells	-0.322849	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	cDCs	-0.26624	3.84e-04
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	-0.39494	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	-0.470601	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	NK cells	-0.527912	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	B cells	-0.301371	2.44e-13
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	-0.298289	1.19e-34
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Plasma cells	0.66143	1.41e-37
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD4+ T cells	-0.283338	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Mono/Macro	-0.560847	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	cDCs	-0.280327	2.84e-08
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD4+ T cells	-0.373039	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Plasma cells	-0.45376	1.40e-19
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD4+ T cells	-0.676823	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	NK cells	-0.329345	5.92e-29
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	pre	Mono/Macro	-0.299187	0.00e+00
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Erythrocytes	-1.10308	4.32e-23
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	CD8+ T cells	0.422154	1.94e-06
GSE164237	patients	Peripheral blood mononuclear cells	Melanoma	Advanced stages of melanoma	Immunotherapy	pembrolizumab	post	CD8+ T cells	0.258317	0.00e+00
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Malignant cells	0.699247	5.15e-05
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	-0.306411	5.99e-08
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	-0.283015	3.25e-04
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	Mono/Macro	-0.44317	0.00e+00
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Malignant cells	-0.634914	4.26e-43
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	B cells	0.614288	1.45e-03
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Erythrocytes	-0.47771	2.31e-22
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	NK cells	-0.276097	1.39e-09
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	Malignant cells	0.362471	3.90e-11
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	NK cells	-0.47588	4.11e-10
GSE139386	H3122 cell line	Cell line	Lung cancer	EML4-ALK fusion-positive non-small cell lung cancer (NSCLC)	Targeted therapy	ceritinib	NA	Malignant cells	0.476039	0.00e+00
GSE161195	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	DARA-KRD (daratumumab + carfilzomib + lenalidomide + dexamethasone)	post	Malignant cells	0.32487	4.76e-21
GSE168668	LNCaP cell line	Cell line	Prostate cancer	Prostate cancer	Targeted therapy	enzalutamide	NA	Malignant cells	-0.283295	0.00e+00
GSE149214	PC9 cell line	Cell line	Lung cancer	EGFR-mutated non-small cell lung cancer (NSCLC)	Targeted therapy	erlotinib	NA	Malignant cells	-0.410102	1.46e-26
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	Malignant cells	0.358146	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	CD4+ T cells	-0.251598	3.77e-17
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	pre	Malignant cells	0.573021	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD8+ T cells	0.462528	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	1.07619	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Erythrocytes	-0.310372	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD8+ T cells	0.355191	8.34e-21
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	B cells	-1.17786	3.25e-07
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD4+ T cells	0.339409	1.00e-18
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Malignant cells	0.590159	0.00e+00
GSE131984_JQ1	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1	NA	Malignant cells	0.339815	0.00e+00
GSE131984_JQ1Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + paclitaxel	NA	Malignant cells	0.364596	0.00e+00
GSE131984_JQ1Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + palbociclib	NA	Malignant cells	0.333171	0.00e+00
GSE108397	451Lu cell line	Cell line	Melanoma	Melanoma	Targeted therapy	PLX-4720	NA	Malignant cells	0.636662	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Malignant cells	-0.302889	0.00e+00
GSE164897_VemCob	A375 cell line	Cell line	Melanoma	BRAFV600E-mutant melanoma	Targeted therapy	vemurafenib + combimetinib	NA	Malignant cells	-1.31599	0.00e+00
GSE164897_VemTra	A375 cell line	Cell line	Melanoma	B+E2:E57RAFV600E-mutant melanoma	Targeted therapy	vemurafenib + trametinib	NA	Malignant cells	-1.83482	0.00e+00

Top

Expression of RPS5 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to RPS5

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating RPS5

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Top

Motifs and transcription factors (TFs) regulating RPS5

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
RPS5	metacluster_191.2	ELK4; NR2C2; NR2C2; NR2C2; NR2C2 (directAnnotation). GABPA (inferredBy_Orthology).
RPS5	metacluster_166.4	BCLAF1; EHF; ELF1; ELF1; ELF1; ELF1; ELF1; ELF1; ELF2; ELF2; ELF4; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK3; ELK3; ELK3; ELK3; ELK4; ERG; ERG; ERG; ERG; ETS1; ETS1; ETS1; ETS1; ETS1; ETV1; ETV1; ETV1; ETV1; ETV2; ETV3; ETV4; ETV4; ETV4; ETV4; ETV4; ETV5; ETV7; FEV; FEV; FLI1; FLI1; FLI1; FLI1; GABPA; GABPA; GABPA; GABPA; GABPA; GABPA; GABPB1; GATAD1; PHF20; ZBTB25; ZBTB40 (directAnnotation). EHF; ELF1; ELF1; ELF3; ELF5; ELK3; ELK4; ERG; ETS1; ETV1; ETV2; ETV4; FLI1; GABPA; GABPA (inferredBy_Orthology).
RPS5	metacluster_191.3	EHF; ELF1; ELF1; ELF1; ELF4; ELK1; ELK3; ELK3; ELK4; ELK4; ERF; ETS1; ETS2; ETV3; ETV4; ETV5; FEV; FEV; FLI1; FLI1; GABPA; GABPA; GABPA; GABPA; GABPA; GABPA; SPDEF; ZNF200 (directAnnotation). ELK1; ELK1; ELK3; ELK3; ELK4; ELK4; ETV1; ETV1; ETV4; ETV4; ETV4; ETV5; GABPA; GABPA (inferredBy_Orthology).
RPS5	cisbp__M02645	ETS1 (directAnnotation).
RPS5	taipale_tf_pairs__FOXO1_ELK3_RCCGGAWGTKKW_CAP	ELK3; FOXO1 (directAnnotation).
RPS5	jaspar__MA1483.2	ELF2 (directAnnotation).
RPS5	taipale_tf_pairs__ELF2_NATGCGGAAGTR_HT	ELF2 (directAnnotation).
RPS5	cisbp__M08198	ELF1 (directAnnotation).
RPS5	taipale_tf_pairs__ERF_FOXI1_RSCGGATGTTKWN_CAP_repr	ERF; FOXI1 (directAnnotation).
RPS5	transfac_pro__M06035	ZNF749 (directAnnotation).
RPS5	metacluster_50.1	BATF; BATF; BATF; BATF; BNC2; FOS; FOSB; FOSL1; FOSL1; IRF4; JUN; JUN; JUNB; JUNB; JUNB; JUNB; JUND; JUND; JUND; JUND; JUND; SMAD2; SMAD3 (directAnnotation). BATF; BATF; BATF; FOS; FOSL1; FOSL2; JDP2; JUN; JUN; JUND (inferredBy_Orthology).
RPS5	metacluster_157.2	ATF3; ATF3; ATF3; BACH1; BACH1; BACH1; BACH2; BACH2; BACH2; BACH2; BATF; BATF; BCL11A; FOS; FOS; FOS; FOS; FOS; FOS; FOSB; FOSL1; FOSL1; FOSL1; FOSL1; FOSL1; FOSL1; FOSL2; FOSL2; FOSL2; JDP2; JDP2; JDP2; JDP2; JDP2; JDP2; JDP2; JUN; JUN; JUN; JUN; JUN; JUNB; JUNB; JUNB; JUNB; JUNB; JUNB; JUND; JUND; JUND; JUND; JUND; JUND; JUND; JUND; JUND; MAF; MAFB; MAFF; MAFG; MAFK; NFE2; NFE2; NFE2; NFE2; NFE2; NFE2; NFE2L1; NFE2L1; NFE2L2; NFE2L3; ZNF3; ZSCAN5C (directAnnotation). FOSL1; JUN; JUN; JUN; JUNB; JUNB; JUND (inferredBy_Orthology).
RPS5	transfac_pro__M05548	PLAGL2 (directAnnotation).
RPS5	metacluster_56.3	HSF2 (directAnnotation).
RPS5	taipale_tf_pairs__ETV2_DLX2_RCCGGAANNNNNYAATTA_CAP	DLX2; ETV2 (directAnnotation).
RPS5	taipale_tf_pairs__GCM2_ONECUT2_RTRCGGGNNNNNNATCRATN_CAP_repr	GCM2; ONECUT2 (directAnnotation).
RPS5	taipale_tf_pairs__ERF_DLX2_RSCGGAANNNNNYMATTA_CAP_repr_2	DLX2; ERF (directAnnotation).
RPS5	metacluster_137.2	ATF3; BACH2; BATF; BATF; BATF; BATF; BATF3; FOS; FOS; FOS; FOS; FOS; FOS; FOS; FOS; FOS; FOS; FOSB; FOSB; FOSB; FOSB; FOSB; FOSL1; FOSL1; FOSL1; FOSL1; FOSL1; FOSL2; FOSL2; FOSL2; FOSL2; FOSL2; FOSL2; FOSL2; INSM2; JUN; JUN; JUN; JUN; JUN; JUN; JUN; JUN; JUN; JUN; JUN; JUN; JUNB; JUNB; JUNB; JUNB; JUNB; JUND; JUND; JUND; JUND; JUND; SMARCC1 (directAnnotation). ATF3; ATF3; BATF; FOS; FOSB; FOSL1; FOSL1; FOSL2; FOSL2; FOSL2; JUN; JUN; JUN; JUN; JUN; JUN; JUN; JUNB; JUND; JUND; JUND; JUND (inferredBy_Orthology).
RPS5	metacluster_2.8	IRF4; IRF5; IRF6; IRF9 (directAnnotation). IRF3; IRF5; IRF5; IRF6 (inferredBy_Orthology).
RPS5	tfdimers__MD00602	MYB; STAT6 (directAnnotation).
RPS5	metacluster_112.5	HOXA4; PAX3; PAX7; PAX7 (directAnnotation).
RPS5	transfac_pro__M06342	ZNF329 (inferredBy_Orthology).
RPS5	taipale_tf_pairs__GCM1_ETV4_RTGCGGGCGGAAGTR_CAP	ETV4; GCM1 (directAnnotation).
RPS5	metacluster_52.10	GTF3C2; ZNF436 (directAnnotation).
RPS5	metacluster_139.7	XBP1 (directAnnotation). XBP1 (inferredBy_Orthology).
RPS5	metacluster_173.2	ATF3; ATF6; ATF6; ATF6; ATF6; ATF6; ATF6; ATF6B; ATF6B; ATF6B; BATF3; CREB3; CREB3; CREB3; CREB3; CREB3; CREB3L1; CREB3L1; CREB3L1; CREB3L1; CREB3L1; CREB3L1; CREB3L1; CREB3L2; CREB3L4; XBP1; XBP1; XBP1; XBP1 (directAnnotation). ATF1; ATF1; ATF1; ATF1; ATF6; ATF6; ATF6; ATF6; ATF6; ATF6B; ATF6B; ATF6B; ATF6B; CREB1; CREB1; CREB3; CREB3; CREB3; CREB3; CREB3L1; CREB3L1; CREB3L1; CREB3L1; CREB3L1; CREB3L2; CREB3L2; CREB3L2; CREB3L2; CREB3L2; CREB3L3; CREB3L3; CREB3L3; CREB3L3; CREB3L4; CREB3L4; CREB3L4; CREB3L4; CREM; CREM; CREM; CREM (inferredBy_Orthology).
RPS5	taipale_tf_pairs__GCM1_ELK1_RTGCGGGCGGAAGTN_CAP_2	ELK1; GCM1 (directAnnotation).
RPS5	taipale_tf_pairs__CEBPG_CREB3L1_NGCCACGCAAYN_CAP_repr	CEBPG; CREB3L1 (directAnnotation).
RPS5	transfac_pro__M04844	MAX (directAnnotation).
RPS5	transfac_pro__M01069	GZF1 (directAnnotation).
RPS5	dbtfbs__E4F1_K562_ENCSR731LHZ_merged_N1	E4F1 (directAnnotation).
RPS5	metacluster_34.4	ETS1; ETS1; ETS1; HCFC1; SIX5; SIX5; SIX5; SIX5; SMARCC2; SMARCC2; THAP11; THAP11; ZNF143; ZNF143; ZNF143; ZNF143 (directAnnotation). TBX2; THAP11; THAP11; ZNF143 (inferredBy_Orthology).
RPS5	swissregulon__hs__ELF2	ELF2 (directAnnotation).
RPS5	metacluster_34.3	EGR1; ETS1; SETDB1; SIX5; SIX5; ZNF143; ZNF76 (directAnnotation).
RPS5	taipale_tf_pairs__ELK1_FOXI1_RSCGGATGTKKN_CAP	ELK1; FOXI1 (directAnnotation).
RPS5	taipale_tf_pairs__FOXO1_ELK1_RSCGGATGTTRTN_CAP	ELK1; FOXO1 (directAnnotation).
RPS5	taipale_tf_pairs__ETV2_RFX5_NNNTTCCGSNNNNGCAACNN_CAP_repr	ETV2; RFX5 (directAnnotation).
RPS5	taipale_tf_pairs__ETV2_FOXO6_RCCGGATGTTKWN_CAP	ETV2; FOXO6 (directAnnotation).
RPS5	taipale_tf_pairs__ETV2_FOXI1_RSCGGATGTTKW_CAP	ETV2; FOXI1 (directAnnotation).
RPS5	nitta__Ets98B_TTCCCC20NTA_KH_TKGCGGATGCN_m1_c3	SPDEF (inferredBy_Orthology).
RPS5	transfac_pro__M06317	ZNF829 (directAnnotation).
RPS5	transfac_pro__M06586	ZNF479 (directAnnotation).
RPS5	transfac_pro__M06742	ZNF304 (directAnnotation).
RPS5	jaspar__MA1633.2	BACH1 (directAnnotation).
RPS5	swissregulon__hs__ZNF784	ZNF784 (directAnnotation).
RPS5	swissregulon__hs__SMAD3	SMAD3 (directAnnotation).
RPS5	transfac_pro__M06355	ZNF841 (directAnnotation).
RPS5	transfac_pro__M06234	ZNF91 (directAnnotation).
RPS5	hocomoco__NKX61_HUMAN.H11MO.1.B	NKX6-1 (directAnnotation).
RPS5	taipale_tf_pairs__HOXB2_RFX5_TAATKRNNNNGCAAC_CAP_repr	HOXB2; RFX5 (directAnnotation).

Page: 1 2 3 4

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

Target name	Drug name	Drug ID	Drug type
RPS5	"Artenimol"	DB11638	small molecule

Page: 1

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."